title: Doxofylline: a "novofylline".
abstract: Xanthines such as theophylline have been used in the treatment of lung diseases since the early 1900's, but have a major drawback of a very narrow therapeutic window and many drug/drug interactions. With the increasing availability of other classes of drugs, this has limited the use of xanthines. Doxofylline is a xanthine molecule that appears to be both bronchodilator and anti-inflammatory with an improved therapeutic window over conventional xanthines such as theophylline and the evidence supporting the effects of doxofylline in the treatment of lung diseases is discussed.
authors.affiliation: Sackler Institute of Pulmonary Pharmacology, King's College London, 5th Floor, Franklin Wilkins Building, 150 Stamford Street, Waterloo Campus, London SE1 9NH, UK. clive.page@kcl.ac.uk
authors.forename: Clive P
authors.initials: CP
authors.lastname: Page
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy / Q000503:physiopathology; D013806:Theophylline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D013806:Theophylline; C029797:doxofylline